QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)

Pharvaris (PHVS) News Today

$22.94
-1.27 (-5.25%)
(As of 02/29/2024 ET)
SourceHeadline
marketbeat.com logoPharvaris (NASDAQ:PHVS) Short Interest Down 49.0% in February
marketbeat.com - February 29 at 8:41 AM
markets.businessinsider.com logoPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE Treatment
markets.businessinsider.com - February 26 at 5:45 AM
msn.com logoPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97
msn.com - February 25 at 2:33 AM
finance.yahoo.com logoPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
finance.yahoo.com - February 22 at 9:45 AM
globenewswire.com logoPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
globenewswire.com - February 22 at 6:50 AM
finance.yahoo.com logoPharvaris Announces Extraordinary Meeting of Shareholders
finance.yahoo.com - February 16 at 7:48 AM
globenewswire.com logoPharvaris Announces Extraordinary Meeting of Shareholders
globenewswire.com - February 16 at 6:50 AM
markets.businessinsider.com logoWedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
markets.businessinsider.com - February 14 at 6:25 PM
finance.yahoo.com logoPharvaris to Present at the WSAAI Annual Meeting 2024
finance.yahoo.com - January 26 at 10:51 PM
markets.businessinsider.com logoBuy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory Advances
markets.businessinsider.com - January 24 at 5:30 AM
finance.yahoo.com logoPharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
finance.yahoo.com - January 23 at 2:29 PM
finanznachrichten.de logoPharvaris N.V.: Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
finanznachrichten.de - January 22 at 8:29 AM
msn.com logoPharvaris rises as FDA lifts hold on hereditary angioedema candidate
msn.com - January 22 at 8:29 AM
markets.businessinsider.com logoPharvaris Says FDA Lifts Clinical Hold On IND For Deucrictibant For Treatment Of HAE Attacks
markets.businessinsider.com - January 22 at 8:29 AM
finance.yahoo.com logoPharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
finance.yahoo.com - January 22 at 8:29 AM
seekingalpha.com logoPharvaris: Digging Deep For Sufficient Market Size
seekingalpha.com - January 17 at 7:45 AM
markets.businessinsider.com logoPositive Clinical Trials and Strong Financial Position Support Buy Rating for Pharvaris
markets.businessinsider.com - January 9 at 8:48 PM
markets.businessinsider.com logoBuy Rating Affirmed for Pharvaris Amid Anticipated Clinical Updates and Positive Trial Prospects
markets.businessinsider.com - January 6 at 8:13 AM
finanznachrichten.de logoPharvaris N.V.: Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
finanznachrichten.de - January 5 at 1:02 PM
finance.yahoo.com logoPharvaris Provides Business Update and Outlines 2024 Strategic Priorities
finance.yahoo.com - January 5 at 8:01 AM
msn.com logoPharvaris (PHVS) Price Target Increased by 38.65% to 32.93
msn.com - December 17 at 12:17 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Pharvaris (PHVS) and Tourmaline Bio (TRML)
markets.businessinsider.com - December 11 at 5:32 PM
finance.yahoo.com logoPharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last week
finance.yahoo.com - December 11 at 7:31 AM
tmcnet.com logoPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
tmcnet.com - December 8 at 7:22 PM
finance.yahoo.com logoPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
finance.yahoo.com - December 8 at 7:22 PM
markets.businessinsider.com logoAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pharvaris (PHVS), Veeva Systems (VEEV) and UnitedHealth (UNH)
markets.businessinsider.com - December 7 at 6:17 PM
msn.com logoBioCryst falls after Pharvaris win for hereditary angioedema drug
msn.com - December 6 at 2:32 PM
markets.businessinsider.com logoTurnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks
markets.businessinsider.com - December 6 at 2:32 PM
investorplace.com logoWhy Is Pharvaris (PHVS) Stock Up 36% Today?
investorplace.com - December 6 at 12:01 PM
msn.com logoPharvaris surges on mid-stage success for hereditary angioedema therapy
msn.com - December 6 at 8:30 AM
markets.businessinsider.com logoPharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
markets.businessinsider.com - December 6 at 8:30 AM
finance.yahoo.com logoPharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
finance.yahoo.com - December 6 at 8:30 AM
morningstar.com logoPharvaris NV Ordinary Shares
morningstar.com - December 5 at 10:20 AM
finance.yahoo.com logoPharvaris to Present at the GA²LEN UCARE Conference 2023
finance.yahoo.com - November 30 at 8:12 AM
benzinga.com logoPharvaris Stock (NASDAQ:PHVS), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 25 at 7:49 AM
finanznachrichten.de logoPharvaris N.V.: Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
finanznachrichten.de - November 15 at 9:09 AM
finance.yahoo.com logoPharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
finance.yahoo.com - November 15 at 9:09 AM
finance.yahoo.com logoPharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
finance.yahoo.com - November 9 at 12:28 PM
markets.businessinsider.com logoPharvaris: Promising Drug Development and Financial Stability Support Outperform Rating and $24 Price Target
markets.businessinsider.com - November 6 at 7:15 PM
finanznachrichten.de logoPharvaris N.V.: Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - November 2 at 10:10 AM
finance.yahoo.com logoPharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 2 at 10:10 AM
msn.com logoPharvaris (PHVS) Price Target Increased by 7.26% to 24.48
msn.com - November 1 at 6:28 PM
finance.yahoo.com logoPharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
finance.yahoo.com - October 30 at 9:24 AM
finance.yahoo.com logoPharvaris To Present at the APAAACI 2023 International Conference
finance.yahoo.com - October 13 at 8:30 AM
finance.yahoo.com logoPharvaris To Present at the CIIC Fall 2023 Conference
finance.yahoo.com - October 4 at 10:00 AM
msn.com logoWedbush Initiates Coverage of Pharvaris (PHVS) with Outperform Recommendation
msn.com - September 26 at 2:46 PM
markets.businessinsider.com logoPharvaris' Promising Oral Treatment Solutions For Treating Swollen Blood Vessels - Analyst Sees 35% Upside
markets.businessinsider.com - September 25 at 6:33 PM
finance.yahoo.com logoPharvaris To Participate in the 2023 Cantor Global Healthcare Conference
finance.yahoo.com - September 19 at 7:41 AM
thestreet.com logoPharvaris N.V.
thestreet.com - September 14 at 7:08 PM
finance.yahoo.com logoPharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
finance.yahoo.com - September 6 at 8:55 AM
Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.



PHVS Media Mentions By Week

PHVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PHVS
News Sentiment

0.51

0.60

Average
Medical
News Sentiment

PHVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PHVS Articles
This Week

5

1

PHVS Articles
Average Week

Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:PHVS) was last updated on 2/29/2024 by MarketBeat.com Staff